Get notified when LONA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Board Designation Rights For Commodore and Tcgx (new) — Two large PIPE investors have the right to designate one board member each as long as they hold 5% or more, giving them significant governance influence.
- Commitment to Cause Resignation of Two Current Board Members Within Six Months (new) — The company agreed to use reasonable best efforts to cause two current board members to resign by June 23, 2026, signaling a board restructuring tied to the financing.
LeonaBio registers resale of up to 58.5M shares by selling stockholders; company gets no proceeds from sales
Filed April 2, 2026 · ~1 min read
Key Changes
-
high
This is a secondary offering: selling stockholders may sell up to 58,464,567 shares, and LeonaBio will not receive any proceeds from those sales.
The Offering verify on EDGAR → -
high
The company could receive up to $146.2M if all eligible warrants are exercised for cash at $6.35 per share, plus a negligible $8,816 from pre-funded warrants.
Use of Proceeds verify on EDGAR → -
medium
Any warrant exercise proceeds are earmarked for working capital and advancing lasofoxifene and other pipeline candidates.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.
Partner
Trade LONA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify